循环肿瘤细胞检测的临床有效性和实用性分析

doi:10.11904/j.issn.1002-3070.2018.02.016

Abstract

Abstract: Circulating tumor cells(CTCs)are a special type of biomarker that can be used as a diagnostic tool to predict the prognosis of multiple tumors.At present,although circulating tumor cells have not been full clinically application,studies on circulating tumor cells have shown high clinical efficacy,especially in the fields of breast cancer,lung cancer,prostate cancer and colorectal cancer.This article reviews the research progress of circulating tumor cells in metastatic cancer and non-metastatic cancer,analyzes the clinical efficacy and practicability of circulating tumor cells.

Key words: Circulating tumor cells, Clinical use, Clinical efficacy

CLC Number:

R730

XU Xunzheng, ZHANG Haogang, QIAO Pengfei, WANG Fujing. Clinical efficacy and practicability analysis of circulating tumor cells[J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(2): 169-173.

References

1 Ferreira MM,Ramani VC,Jeffrey SS.Circulating tumor cell technologies[J].Molecular Oncology,2016,10(3):374-394.
2 Kirby BJ,Jodari M,Loftus MS,et al.functional characterization of circulating tumor cells with a prostate-cancer-specific microfluidic device[J].PLoS One,2012,7(4):e35976.
3 Mayer JA,Pham T,Wong KL,et al.FISH-based determination of HER2 status in circulating tumor cells isolated with the microfluidic CEE^TM platform[J].Cancer Genetics,2011,204(11):589-595.
4 Kanwar N,Hu P,Bedard P,et al.Identification of genomic signatures in circulating tumor cells from breast cancer[J].Int J Cancer,2015,137(2):332-344.
5 Chimonidou M,Kallergi G,Georgoulias V,et al.Breast cancer metastasis suppressor-1 promoter methylation in primary breast tumors and corresponding circulating tumor cells[J].Mol Cancer Res,2013,11(10):1248-1257.
6 Chimonidou M,Kallergi G,Georgoulias V,et al.Breast cancer metastasis suppressor-1 promoter methylation in primary breast tumors and corresponding circulating tumor cells[J].Mol Cancer Res,2013,11(10):1248-1257.
7 Mostert B,Sieuwerts AM,Kraan J,et al.Gene expression profiles in circulating tumor cells to predict prognosis in metastatic breast cancer patients[J].Ann Oncol,2015,26(3):510-516.
8 Khoo BL,Warkiani ME,Tan DS,et al.Clinical validation of an ultra high-throughput spiral microfluidics for the detection and enrichment of viable circulating tumor cells[J].PLoS One,2014,9(10):e99409.
9 Ligthart ST,Bidard FC,Decraene C,et al.Unbiased quantitative assessment of Her-2 expression of circulating tumor cells in patients with metastatic and non-metastatic breast cancer[J].Ann Oncol,2013,48(5):1231-1238.
10 Scher HI,Graf RP,Schreiber NA,et al.Nuclear-specific AR-V7 protein localization is necessary to guide treatment selection in metastatic castration-resistant prostate cancer[J].European Urology,2017,71(6):874-882.
11 Mazel M,Jacot W,Pantel K,et al.Frequent expression of PD‐L1 on circulating breast cancer cells[J].Molecular Oncology,2015,9(9):1773-1782.
12 Paoletti C,Larios JM,Muñiz MC,et al.Heterogeneous estrogen receptor expression in circulating tumor cells suggests diverse mechanisms of fulvestrant resistance[J].Molecular Oncology,2016,10(7):1078-1085.
13 Bidard FC,Proudhon C,Pierga JY.Circulating tumor cells in breast cancer[J].Molecular Oncology,2016,10(3):418-430.
14 Loh J,Jovanovic L,Lehman M,et al.Circulating tumor cell detection in high-risk non-metastatic prostate cancer[J].J Cancer Res Clin Oncol,2014,140(12):2157-2162.
15 Thalgott M,Rack B,Horn T,et al.Detection of circulating tumor cells in locally advanced high-risk prostate cancer during neoadjuvant chemotherapy and radical prostatectomy[J].Anticancer Research,2015,35(10):5679-5685.
16 Fiorelli A,Accardo M,Scrima M,et al.Circulating tumor cells in diagnosing lung cancer:clinical and morphologic analysis[J].Ann Thorac Surg,2015,99(6):1899-1905.
17 Ilie M,Hofman V,Long-Mira E,et al.“Sentinel” circulating tumor cells allow early diagnosis of lung cancer in patients with chronic obstructive pulmonary disease[J].PLoS One,2014,9(10):e111597.
18 Bidard F,Peeters DJ,Fehm T,et al.Clinical validity of circulating tumour cells in patients with metastatic breast cancer:a pooled analysis of individual patient data[J].Lancet Oncology,2014,15(4):406-414.
19 Huang X,Gao P,Song Y,et al.Meta-analysis of the prognostic value of circulating tumor cells detected with the Cell Search System in colorectal cancer[J].BMC Cancer,2015,15(1):202.
20 Rahbari NN,Aigner M,Thorlund K,et al.Meta-analysis shows that detection of circulating tumor cells indicates poor prognosis in patients with colorectal cancer[J].Gastroenterology,2010,138(5):1714-1726.
21 Tol J,Koopman M,Miller MC,et al.Circulating tumour cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agents[J].Ann Oncol,2010,21(5):1006-1012.
22 Sastre J,Maestro ML,Gómezespaña A,et al.Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab:A Spanish cooperative group for the treatment of digestive tumors study[J].Oncologist,2012,17(7):947-955.
23 Krebs MG,Renehan AG,Backen A,et al.Circulating tumor cell enumeration in a phase II trial of a four-drug regimen in advanced colorectal cancer[J].Clinical Colorectal Cancer,2015,14(2):115-122.
24 V Vlaeminckguillem.When prostate cancer circulates in the bloodstream[J].Diagnostics(Basel),2015,5(4):428-474.
25 Scher HI,Heller G,Molina A,et al.Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer[J].J Clin Oncol,2015,33(12):1348-1355.
26 Bidard FC,Michiels S,Mueller V,et al.International MEta-analysis of circulating tumor cell detection in early breast cancer patients treated by NEO adjuvant chemotherapy[J].Cancer Research,2017,77(4 Supplement):31.
27 Pierga JY,Bidard FC,Autret A,et al.Circulating tumour cells and pathological complete response:independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials(BEVERLY-1 and-2)of neoadjuvant chemotherapy combined with bevacizumab[J].Ann Oncol,2016,28(1):103-109.
28 Rack B,Schindlbeck C,Jückstock J,et al.Circulating tumor cells predict survival in early average-to-high risk breast cancer patients[J].J Natl Cancer Inst,2014,106(5):2504-2511.
29 Sotelo MJ,Sastre J,Maestro ML,et al.Role of circulating tumor cells as prognostic marker in resected stage III colorectal cancer[J].Ann Oncol,2015,26(3):535-541.
30 Clara BL,Ortega FG,Antonio CLDG,et al.Circulating tumor cells identify early recurrence in patients with non-small cell lung cancer undergoing radical resection[J].PLoS One,2016,11(2):e0148659.
31 Heidary M,Auer M,Ulz P,et al.The dynamic range of circulating tumor DNA in metastatic breast cancer[J].Breast Cancer Res,2014,16(4):421.
32 Tie J,Wang Y,Tomasetti C,et al.Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer[J].Science Translational Medicine,2017,11(2):117-118.
33 de Bono JS,Scher HI,Montgomery RB,et al.Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer[J].Clin Cancer Res,2008,14(19):6302-6309.
34 Goldkorn A,Ely B,Quinn DI,et al.Circulating tumor cell counts are prognostic of overall survival in SWOG S0421:a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer[J].J Clin Oncol,2014,32(11):1136-1142.
35 Pearl ML,Dong H,Tulley S,et al.Treatment monitoring of patients with epithelial ovarian cancer using invasive circulating tumor cells(iCTCs)[J].Gynecologic Oncology,2015,137(2):229-238.
36 Ma J,Yao S,Li XS,et al.Neoadjuvant therapy of DOF regimen plus bevacizumab can increase surgical resection ratein locally advanced gastric cancer:A randomized,controlled study[J].Medicine,2015,94(42):e1489.
37 Bidard FC,Pierga JY,Soria JC,et al.Translating metastasis-related biomarkers to the clinic-progress and pitfalls[J].Nat Rev Clin Oncol,2013,10(3):169-179.
38 Bidard FC,Pierga JY.Clinical utility of circulating tumor cells in metastatic breast cancer[J].J Clin Oncol,2015,33(14):1622.
39 Georgoulias V,Bozionelou V,Agelaki S,et al.Trastuzumab decreases the incidence of clinical relapses in patients with early breast cancer presenting chemotherapy-resistant CK-19 mRNA-positive circulating tumor cells:results of a randomized phase II study[J].Ann Oncol,2012,23(7):1744-1750.

[1]	LUO Bin ,SHI Qihui ,LIU Jiaxiang ,TIAN Jianhui. The clinical significance of circulating tumor cells in lung cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(4): 370-374.
[2]	CAI Li, SONG Xiaowei, PAN Lihua, SHI Guangyue, LIU Wei, SUN Lichun, CHEN Xuesong, ZHAO Lina. The significance of epithelial mesenchymal transitions gene Twist in circulating tumor cells to efficacy of chemotherapy in metastatic breast cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2013, 27(1): 37-41.
[3]	TANG Dabei,ZHANG Qingyuan,WANG Jingxuan,ZHAO Shu,ZHAO Wenhui. A clinical study of estradiol therapy in endocrine-resistant advanced breast cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2012, 26(4): 289-292.
[4]	QIAN Liuqi,LIU Qian,LIU Yi,ZHANG Shaohua,WANG Tao,WU Shikai,SONG Santai,LIU Bing,JIANG Zefei. Expression of circulating tumor cells in metastatic breast cancer patients and its relationship with multiple serum tumor markers [J]. PRACTICAL ONCOLOGY JOURNAL, 2012, 26(3): 220-224.

Clinical efficacy and practicability analysis of circulating tumor cells

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 4

Recommended Articles

Metrics

Comments